OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-06-30-accounts

COMPANY REGISTRATION NUMBER : 7225131

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE UNAUDITED FINANCIAL STATEMENTS FOR YEAR ENDED 30 JUNE 2023

Charity Number : 1136067

Edmund Carr LLP

Chartered Accountants 146 New London Road

Chelmsford Essex CM2 OAW

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

----- Start of picture text -----
CONTENTS PAGE
Company information 1
Trustees' annual report 2
Independent Examiner's report to the Trustees 12
Statement of financial activities 13
Balance sheet 14
Notes to the financial statements 15
----- End of picture text -----

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

COMPANY INFORMATION

YEAR ENDED 30 JUNE 2023

Charity Number 1136067 Company Number 7225131 Registered Office 38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Mr Zaed Hamady Professor Michael Douek Professor Anant Desai Mr Michael Shackcloth Mr John Whiting Professor Jim Khan

Mr Avi Agrawal Mr Edmund Leung Professor Derek Manas Mr Aaron Quyn Mr Paul Skaife Mrs Abigail Tomlins Professor Jayant Vaidya

President Vice President Honorary Secretary Honorary Treasurer EJSO Representative Meeting Secretary

(Resigned 20/11/2022) (Appointed 20/11/2022) (Deputy Meeting Secretary)

-1-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT

YEAR ENDED 30 JUNE 2023

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2023. The Trustees of the charity as shown above are also the directors of the charity.

Objectives and Activities

The Charity’s objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and to promote research, training, and education in surgical oncology for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals in all surgical cancer specialties and cancer research. In addition, the Society focuses on innovation in cancer care, support the training and development of future workforce, and carefully consider the Charity Commission’s guidance on public benefit when determining our activities.

Portfolio of BASO Prizes and Awards

The Association takes immense pride in its array of awards dedicated to inspiring our junior colleagues and nurturing their passion for surgical oncology, cancer research and patient care. Follow link for more details: https://baso.org.uk/education-training.aspx. The Society continues awarding the following prizes at its annual scientific meeting:

To expand its commitment to all cancer-related professionals, BASO announced the following new prizes:

In addition, BASO annually provides a range of prizes to foster and promote trainee’s enthusiasm for surgical oncology. These prizes are awarded to the trainee who delivers the best surgical oncology presentation at the various surgical specialty associations’ annual scientific conferences.

-2-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Over the years, BASO has curated a prestigious collection of Awards presented to surgeons in recognition of their exceptional accomplishments and contributions to cancer surgery; its research and education.

In addition to Ronald Raven Lifetime Achievement Award , Geoff Oats Award and Uccio Querci della Rovere Award , this year BASO inaugurated - BASO Medal for Excellence to mark the 50th Anniversary of the founding of the Association. The British Association of Surgical Oncology Medal for Excellence is presented to acknowledge the significant contributions made by individual surgeon or team in advancing cancer care, excelling in research, clinical practice, education and innovation. This prestigious international award will be presented every five years, welcoming nominations from both members and non-members of the Association, in recognition of their remarkable contributions to cancer surgery in the UK. BASO took great pride in awarding the inaugural medal to Professor Freddie Hamdy in July 2022. Follow link for more details: https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx

BASO Grants

BASO continues growing its portfolio of research grants to support research. Follow link for more details: https://baso.org.uk/education-training.aspx

Ronald Raven Travelling Fellowship – was endowed in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the Founder of the Association. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment.

BASO (NIHR) Research Project Grant - BASO is a non-commercial partner with the National Institute of Health Research (NIHR) and delivered a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant was open for discrete projects and the studies awarded this grant are automatically eligible for consideration for the Clinical Research Network Support, thereby, are considered for being the portfolio studies. In 2021, BASO announced a new Research Grant in Cancer Surgery, in collaboration with the Rosetrees Trust which will supplant the BASO (NIHR) Research Project Grants starting from 2022.

BASO/Rosetrees Research Grants in Cancer Surgery – To commemorate BASO’s 50[th] Anniversary, the BASO National Committee announced a new initiative, a three-year research grants (in cancer surgery) partnership with the Rosetrees Trust. This collaborative effort will award research grants of up to £50,000 annually, with matching funds provided by the Rosetrees Trust.

The first round of the grants were awarded at BASO’s 50th Anniversary Celebration meeting. Successful applications will be eligible for inclusion in the NIHR portfolio and are encouraged to gain support from a Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU).

-3-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2023

Endorsement of Regional Events

The Association aspires to engage with oncologists and Societies on the regional level. Through its network of Regional Representatives, BASO has supported various regional and national meetings this accounting year.

Engagement with Medical Students

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students, those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives.

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures.

BASO Trainees Group

The BASO Trainees group has continually expanded its horizons and strengthened connections with trainees groups across UK and Europe. These collaborations have enabled us to inspire trainees in tenets of research and clinical excellence in surgical oncology, achieved through the sponsorship of prizes and sponsored lectures at national specialty meetings. Our Trainees remains dedicated to promoting research, academic training, and fellowships.

BASO’s contribution to NICE consultations and Cancer CRGs

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations and guidelines as requested by NICE. Our Council members sit on various Cancer CRG’s, offering expert advice.

Overall, the Society maintains robust relationships with all the surgical societies and the Royal Colleges while actively seeking collaborative opportunities.

Achievements and Performance

The Society continues to support the training and educational needs of our colleagues and address the challenges faced post pandemic. BASO has demonstrated the need for an umbrella organisation to speak with one voice, and is growing its membership, maintained steady finances and retuned to a successful inperson meeting post pandemic.

BASO Annual Scientific Meeting

It was exciting to return to an in-person BASO Annual Scientific Meeting in 2022 after what has undoubtedly been a challenging couple of years for all. The meeting was themed “multidisciplinary cancer management- evolving role of surgical oncology”, and was delivered under the leadership of BASO President, Mr Zaed Hamady, along with Professor Jim Khan as the Meeting Secretary and Professor Jayant Vaidya as the Deputy Meeting Secretary.

-4-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2023

The conference was designed with dedicated plenary sessions and roundtable discussion style sessions for the wide range of disciplines, bringing a network of professionals cross-referencing ideas and learning opportunities. The feedback from surgical delegates has been extremely positive, especially with return to in-person meeting, offering a much broader networking opportunity, particularly for our junior colleagues.

The programme was facilitated by the National and International experts in the field of cancer surgery. Guest speakers included Professor Mike Dixon, Professor Mark Emberton, Professor George Hanna, Professor Richard Heald, Professor Isabel-Teresa Rubio, Miss Jennifer Rusby, Professor Peter Sagar, Professor Irving Taylor, and many more. The programme focussed on the best of practice of surgical oncology. The meeting, provided a great opportunity to learn about surgical cancer research and management in a wide range of surgical specialties. There was an excellent programme for both experienced consultants in surgery and for trainees - both those trainees interested in a surgical oncology career and also those not yet committed to a particular surgical discipline.

The BASO Trainees Day had several prominent speakers who gave us an insight into a full range of topics. These include the role of technology in improving survival and cancer patient outcomes, key issues in peri-operative care of cancer patients, an MDT round table discussion on challenging clinical cases and a session on how to develop a career in cancer surgery.

Approx. 100 abstracts were received, and 7 abstract prizes were awarded for best abstract presentations. The meeting also saw several prestigious eponymous lifetime achievement awards and orations, including the RCS’s Sir Stanford Cade Lecture, given to some of the leading surgeons of our times.

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable.

BASO’s Golden Jubilee Celebrations

BASO, as you know, is one of the oldest cancer surgery associations, founded in 1971 to further the philosophy that the management of malignant disease was becoming a multidisciplinary challenge. The association has since developed and expanded to advance the science, practice, and art of surgical oncology for the benefit of patients and relatives with cancer; and to promote research, training, and education in surgical oncology and to disseminate the useful results of that research appropriately.

It was indeed honour to celebrate BASO’s 50th anniversary alongside esteemed guests and members on 2[nd] July 2022. We extend our heartfelt gratitude to everyone who contributed to the success of BASO’s Golden Jubilee. The Society has achieved an impressive amount in its 50 years, it was a privilege to recognise the achievements of our dedicated colleagues, members, juniors and friends who have played a pivotal role in shaping the Society’s success.

European Journal of Surgical Oncology

The EJSO, co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2022 impact factor were released earlier in June.

The EJSO impact factor has moved to 3.8. (Follow link for more details:

https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). There has been a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief).

-5-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Network and links with other organisations

The Association continues to develop and strengthen its links with other specialties, including establishing membership ties with other specialties, offering consultations, providing mentoring opportunities, and forging partnerships for joint conferences in future.

Simultaneously, the BASO Trainees Group is also proactively expanding its network and holds representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the most outstanding surgical oncology presentations at the Annual ASiT Conference and the SCTS Annual Meetings.

To promote collaborative work, BASO Trainees has joined forces with Dukes Club and Roux Club, and recently collaborated with BONUS to engage with medical students interested in pursuing surgical oncology.

European Society of Surgical Oncology

BASO maintains a strong relationship with its European sister society ESSO. As per the MoU agreed between both the Societies, BASO members have the privilege to enjoy the full standard membership benefits offered by ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. Additionally, BASO members also get the opportunity to apply to an international career development programme, and access to the membership restricted areas on the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly.

National Clinical Guidelines

BASO maintains a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE’s Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

BASO Council is pleased to announce its representation as a stakeholder in the All-Party Parliamentary Group on Cancer. BASO is the only organisation representing the surgical community at this group and the BASO Council is confident that this offers BASO a strong position to discuss with policymakers and lobby for the benefit of oncology surgeons.

Health and Social Care Committee Cancer Services Expert Panel

BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO’s concerns, and raised the Society’s profile and engagement.

BASO@ UK Oncology Forum

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs and is free for BASO members to attend. The meeting is focused on oncologists and offers BASO a strong presence. BASO Council aims to develop this collaboration further.

-6-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2023

BASO@ Oncology Professional Care

Following the success of last year’s collaboration, this year, BASO partnered with the OPC23, and delivered afternoon sessions at the meeting held at London ExCel, and facilitated four sessions on each day. The meeting is designed for Clinical Nurse Specialists, Oncology Nurse Leads, Cancer Researchers, Staff Grade Doctors, Palliative Medicine Consultants, Cancer Pharmacists, and Radiographers etc.

The meeting was a resounding success, boasting an impressive attendance of approx..1600 delegates, with 619 participating in eight BASO sessions. Notably, this meeting was generously sponsored by the industry partners, rendering it free for BASO members and non-members, while also being CPD accredited.

Under the term of our partnership, BASO received a flat fee of £7500 and secured representation on the programme board. Encouraged by the success of this meeting, BASO Council is actively exploring opportunities for continued and expanded partnership for 2024.

Cancer Services Committee

BASO chaired the RCSENG’s Cancer Services Committee (CSC) over a period of time. The CSC has representatives from all surgical disciplines and has served as a focus to communicate the views of surgery as a whole on issues of cancer care. It is the view of the Committee that this forum provides an environment where Surgical Oncology is able to develop a united voice on major issues. The Committee had representations from various surgical societies, Royal Colleges, patient liaison group and Macmillan and acted as a platform to voice the concerns of the cancer services.

However, the CSC is suspended since May 2022, pending a review by the College to assess its functionality and objectives.

BASO Publications

This year, BASO joined ITN business for the World Cancer Day for ‘working together: to tackle cancer’ campaign. The programme collaborated with various organisations and showcased the scientific advances in treatment, raised awareness of subjects concerning people living with cancer and highlighted how early diagnosis and a collaborative approach are key to a better future for patient outcomes. Click here to watch BASO interview: https://workingtogether.itn.co.uk/

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists.

-7-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

Financial Review

Membership

Membership of the Association has remained steady throughout the year. In response to the recent increase in operational costs due to inflation rates, a nominal increase was unanimously agreed upon for all subscription categories at 2022 AGM. This adjustment ensures that we can effectively cover the rising functional expenses.

As agreed at the 2017 AGM, BASO extends a 50% discounted fee on Full Membership of the BASO~ACS for a period of two years to a BASO Trainees member who have completed their training. This benefit is available to those who have maintained continuous membership in the Society for two consecutive years as paying members.

EJSO

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9th December 2020. Elsevier paid a one-off signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO.

This new agreement with added benefits and revenues for both the Societies began on 1st January 2021 and shall conclude on 31st December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO.

The Journal has generated a healthy profit for BASO~ACS in 2022 with an income of £98,634 after the deduction of BASO’s membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

  1. BASO/Rosetrees Research Grants in Cancer surgery 2022 is awarded to:

  2. Miss Bhamini Wadhwana - Assessment of the fungal mycobiome and its volatile organic signature for earlier detection of oesophagogastric cancer

  3. Mr Jayan George - Assessing frailty and its impacts on older patients facing bowel cancer surgery

  4. Ronald Raven Travelling Fellowship Grant of £3,000 in total was awarded to:

  5. Michael Boland ,Consultant Oncoplastic Breast Surgeon, Imperial Healthcare Trust, London

  6. Trevor Yeung , Fellow in Colorectal Surgery, Peter MacCallum Cancer Centre, Australia

  7. BASO Trainees Prize were awarded at the following external meetings:

  8. SCTS Annual Scientific Meeting

  9. ASiT Annual Conference

  10. BONUS Annual Meeting

-8-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2023

BASO Annual Meeting 2022

BASO Trustees strongly feel that the Charity’s continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting.

The meeting was supported by industry sponsorship, however, due to higher logistic charges as applicable for London based meetings, the 2022 Annual Conference incurred a loss. This loss was planned and allowed for in the accounts as the National Committee made the decision to fully sponsor the trainees meeting and offering subsidised registration to juniors. It was felt that a successful meeting was needed to fulfil our charitable aims and that a successful meeting would lead to increased membership of the Society.

The conference raised the Association’s presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure.

Structure, Governance and Management

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work cooperatively together.

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage.

The Ordinary Members of the BASO~ACS National Committee and the Honorary Officer position of Vice President (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a ‘Call for Nominations’. Officer posts (bar the Vice President position) are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM.

-9-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

BASO~ACS has National Committee meetings four times a year. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e- mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake.

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. Free reserves held at the year end, being unrestricted funds not represented by fixed assets, totalled £254,096. The level of reserves, and income from conferences and subscriptions, is crucial to the Association’s work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association’s reserves.

Plans for the Future

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 2022-23. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process.

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association’s distinctive “brand” as the umbrella Society for all Cancer Surgeons.

To this end, in 2010-23 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients.

-10-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2023

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery.

BASO will continue to fund research grants in partnership with Rosetrees Trust to support surgical oncology research. This initiative will foster increasing the breadth of surgical research, and the shortlisted studies will be suitable for inclusion in the NIHR portfolio studies.

BASO will extend its sponsorship and support to regional level meetings, and Student Surgical Societies.

BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery.

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 6 November 2023 and signed on their behalf by:

.........................................

Mr Michael Shackcloth Honorary Treasurer

-11-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

YEAR ENDED 30 JUNE 2023

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2023 which are set out on pages 13 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

.....................................

C A Barker FCA

Edmund Carr LLP 146 New London Road Chelmsford CM2 0AW

16 November 2023

-12-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 30 JUNE 2023

Note
£
£
INCOME from:
Charitable activities:
Members' subscriptions
34,442
-
BASO Conference and Meetings
2
38,445
-
Publications - EJSO
111,143
-
Other trading activities
-
-
Investments
3
728
769
TOTAL INCOME
184,758
769
EXPENDITURE on:
Charitable activities
Subscriptions - ESSO
9,165
-
BASO Conference and Meetings
2
65,896
-
Publications - EJSO
12,509
-
Fellowships & awards
4
28,027
4,000
National Committee and support costs 5
95,296
-
TOTAL EXPENDITURE
210,893
4,000
NET INCOME/(EXPENDITURE)
(26,135)
(3,231)
Transfers between funds
-
-
NET MOVEMENT IN FUNDS
(26,135)
(3,231)
RECONCILIATION OF FUNDS
Total funds brought forward
280,620
29,504
Total funds carried forward
254,485
26,273
Unrestricted
Funds
Funds
Restricted		 Total Funds
2023
£
34,442
38,445
111,143
-
1,497
185,527
9,165
65,896
12,509
32,027
95,296
214,893
(29,366)
-
(29,366)
310,124
280,758		 Total Funds
2022
£
33,949
18,670
80,270
10
181
133,080
7,464
10,184
10,781
14,669
68,045
111,143
21,937
-
21,937
288,187
310,124

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 15 to 20 form part of these financial statements.

-13-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

BALANCE SHEET AS AT 30 JUNE 2023

Note
FIXED ASSETS
Tangible assets
10
CURRENT ASSETS
Debtors
11
Cash at bank
CREDITORS: Amounts falling due
within one year
12
NET CURRENT ASSETS
TOTAL ASSETS LESS CURRENT LIABILITIES
NET ASSETS
FUNDS
Unrestricted
13
Restricted
14
TOTAL FUNDS		 £
£
389
10,685
356,089
366,774
(86,405)
280,369
280,758
280,758
254,485
26,273
280,758
2023		 £
£
566
19,122
362,103
381,225
(71,667)
309,558
310,124
310,124
280,620
29,504
310,124
2022

For the year ending 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 6 November 2023 and are signed on their behalf by:

…................................................... …................................................... MR ZAED HAMADY MR MICHAEL SHACKCLOTH

Company Registration Number: 7225131

The notes on pages 15 to 20 form part of these financial statements.

-14-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment 25% reducing balance Fixtures & fittings 25% reducing balance

-15-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES

SCIENTIFIC CONFERENCE AND MEETINGS

Income
BASO Conference Fees
Lecture grants
Other meetings
Expenditure
BASO Conference
BASO 50th Anniversary Meeting
Other meetings		 Unrestricted
Funds
£
28,945
2,000
7,500
38,445
43,013
12,456
10,427
65,896		 Restricted
Funds
£
-
-
-
-
-
-
-
-		 Total Funds
2023
£
28,945
2,000
7,500
38,445
43,013
12,456
10,427
65,896		 Total Funds
2022
£
16,670
2,000
-
18,670
10,184
-
-
10,184

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

Ronald Raven Prize
Ronald Raven Travel Scholarships
Alan Edwards Memorial Fund
BASO/Rosetrees Research Grant
NIHR Project Grants
Other awards and medals
2022		 Unrestricted
Funds
£
-
-
-
25,000
-
3,027
28,027
10,669		 Restricted
Funds
£
600
3,000
400
-
-
-
4,000
4,000		 Total Funds
2023
£
600
3,000
400
25,000
-
3,027
32,027
14,669		 Total Funds
2022
£
600
3,000
400
-
7,750
2,919
14,669

-16-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

5. NATIONAL COMMITTEE & SUPPORT COSTS

Staff salaries and pension costs
Other support costs
Governance costs (note 6)
2022
6. GOVERNANCE COSTS
Accounting and payroll services
Independent examination fee
Fees payable to independent examiner
Bank charges
Legal and professional fees
7. STAFF COSTS AND EMOLUMENTS
Total staff costs were as follows:
Wages & salaries
Pension costs (defined contribution scheme)
National committee costs		 Unrestricted
Funds
£
53,206
2,058
16,352
23,680
95,296
68,045
Unrestricted
Funds
£
3,919
620
4,539
389
18,752
23,680		 Restricted
Funds
£
-
-
-
-
-
-
Restricted
Funds
£
-
-
-
-
-
-		 Total Funds
2023
£
53,206
2,058
16,352
23,680
95,296
68,045
Total Funds
2023
£
3,919
620
4,539
389
18,752
23,680
2023
£
48,726
4,480
53,206		 Total Funds
2022
£
50,111
1,457
11,798
4,679
68,045
Total Funds
2022
£
3,253
590
3,843
391
445
4,679
2022
£
46,394
3,717
50,111

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8) (2022 - 1 employee and 0.8 FTE)

No employee received remuneration of more than £60,000 during the period.

-17-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

8. NET OUTGOING RESOURCES FOR THE YEAR

----- Start of picture text -----
|||| |---|---|---| |2023|2022| |This is stated after charging:|£|£| |Depreciation|177|138|

----- End of picture text -----

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period. Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company. Expenses totalling £848 were reimbursed to 5 trustees during the period (2022 - £760 to 4 Trustees).

10. TANGIBLE FIXED ASSETS

----- Start of picture text -----
||||| |---|---|---|---| |Computer|Fixtures| |equipment|& fittings|Total| |£|£|£| |COST| |At 1 July 2022|3,060|2,421|5,481| |Additions|-|-|-| |Disposals|(369)|(839)|(1,208)| |At 30 June 2023|2,691|1,582|4,273| |DEPRECIATION| |At 1 July 2022|2,501|2,414|4,915| |Charge for the year|170|7|177| |Disposals|(369)|(839)|(1,208)| |At 30 June 2023|2,302|1,582|3,884| |NET BOOK VALUE| |At 30 June 2023|389|-|389| |At 30 June 2022|559|7|566| |11.|DEBTORS| |2023|2022| |£|£| |Trade debtors|-|300| |Prepayments and Accrued income|10,685|5,706| |Other Debtors|-|13,116| |10,685|19,122|

----- End of picture text -----

-18-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2023

12. CREDITORS: Amounts falling due within one year

Trade creditors
Accruals
Deferred income		 2023
£
-
26,317
60,088
86,405		 2022
£
482
11,117
60,068
71,667

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year
General unrestricted funds
Prior year
General unrestricted funds
14. RESTRICTED FUNDS
Current year
a)
Alan Edwards Memorial Fund
b)
Ronald Raven Prize Fund
c)
Ronald Raven Travelling
Fellowship Fund		 Balance at
01/07/2022
£		 Incoming
Outgoing
Transfers
£
£
£
Movement in resources:		 Incoming
Outgoing
Transfers
£
£
£
Movement in resources:		 Balance at
30/06/2023
£
280,620 184,758
(210,893)		 - 254,485
Balance at
01/07/2020
£		 Incoming
Outgoing
£
£		 Transfers
£		 Balance at
30/06/2021
£
254,732 133,031
(107,143)		 - 280,620
Balance at
01/07/2022
£
5,178
1,876
22,450
29,504		 Incoming
Outgoing
Transfers
£
£
£
153
(400)
-
291
(600)
-
325
(3,000)
-
769
(4,000)
-
Movement in resources:		 Balance at
30/06/2023
£
4,931
1,567
19,775
26,273

-19-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2023

14. RESTRICTED FUNDS

Prior year
a)
Alan Edwards Memorial Fund
b)
Ronald Raven Prize Fund
c)
Ronald Raven Travelling
Fellowship Fund		 Balance at
01/07/2021
£
5,569
2,469
25,417
33,455		 Movement in resources:
Incoming
Outgoing
£
£
9
(400)
7
(600)
33
(3,000)
49
(4,000)		 Transfers
£
-
-
-
-		 Balance at
30/06/2022
£
5,178
1,876
22,450
29,504

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

Current year
Restricted funds
Unrestricted funds
Prior year
Restricted funds
Unrestricted funds		 Tangible
fixed assets
£
-
389
389
Tangible
fixed assets
£
-
566
556		 Other net
assets
£
26,273
254,096
280,369
Other net
assets
£
29,504
280,054
309,558		 Total
£
26,273
254,485
280,758
Total
£
29,504
280,620
310,124

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

-20-